ELECTIVE TESTICULAR BIOPSY DURING CHEMOTHERAPY FOR CHILDHOOD LEUKAEMIA IS OF NO CLINICAL VALUE

Ching Hon Pui, W. Paul Bowman, Minnie Abromowitch, Gary V. Dahl, Bhaskar N. Rao, Judith Ochs, Gaston Rivera

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The clinical value of early detection of testicular leukaemia was assessed by elective wedge biopsy during the 12th or 18th month of therapy in children with acute lymphoblastic leukaemia. Biopsy samples were taken in 106 of 238 consecutively treated boys who attained complete remission; only 1 had occult disease. Samples were also taken in 2 boys with testicular leukaemia at diagnosis as soon as they achieved complete remission, and in 14 others at the end of therapy; none showed evidence of leukaemic infiltration. 13 boys, including the 1 with biopsy-confirmed occult disease, had a testicular relapse; 6 of these patients had had negative biopsy findings 12-28 months before relapse. These results indicate that elective testicular biopsy during therapy for childhood leukaemia is of no benefit clinically. They also suggest that routine use of end-of-therapy testicular biopsy should be re-evaluated, since frequency of testicular relapse is low, therapy is effective, and negative biopsy findings do not preclude eventual relapse.

Original languageEnglish
Pages (from-to)410-412
Number of pages3
JournalThe Lancet
Volume326
Issue number8452
DOIs
StatePublished - 24 Aug 1985

Fingerprint

Leukemia
Biopsy
Drug Therapy
Recurrence
Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Cite this

Pui, Ching Hon ; Paul Bowman, W. ; Abromowitch, Minnie ; Dahl, Gary V. ; Rao, Bhaskar N. ; Ochs, Judith ; Rivera, Gaston. / ELECTIVE TESTICULAR BIOPSY DURING CHEMOTHERAPY FOR CHILDHOOD LEUKAEMIA IS OF NO CLINICAL VALUE. In: The Lancet. 1985 ; Vol. 326, No. 8452. pp. 410-412.
@article{b34d9cd821ab49d990d258fbc29503ee,
title = "ELECTIVE TESTICULAR BIOPSY DURING CHEMOTHERAPY FOR CHILDHOOD LEUKAEMIA IS OF NO CLINICAL VALUE",
abstract = "The clinical value of early detection of testicular leukaemia was assessed by elective wedge biopsy during the 12th or 18th month of therapy in children with acute lymphoblastic leukaemia. Biopsy samples were taken in 106 of 238 consecutively treated boys who attained complete remission; only 1 had occult disease. Samples were also taken in 2 boys with testicular leukaemia at diagnosis as soon as they achieved complete remission, and in 14 others at the end of therapy; none showed evidence of leukaemic infiltration. 13 boys, including the 1 with biopsy-confirmed occult disease, had a testicular relapse; 6 of these patients had had negative biopsy findings 12-28 months before relapse. These results indicate that elective testicular biopsy during therapy for childhood leukaemia is of no benefit clinically. They also suggest that routine use of end-of-therapy testicular biopsy should be re-evaluated, since frequency of testicular relapse is low, therapy is effective, and negative biopsy findings do not preclude eventual relapse.",
author = "Pui, {Ching Hon} and {Paul Bowman}, W. and Minnie Abromowitch and Dahl, {Gary V.} and Rao, {Bhaskar N.} and Judith Ochs and Gaston Rivera",
year = "1985",
month = "8",
day = "24",
doi = "10.1016/S0140-6736(85)92735-7",
language = "English",
volume = "326",
pages = "410--412",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Ltd",
number = "8452",

}

ELECTIVE TESTICULAR BIOPSY DURING CHEMOTHERAPY FOR CHILDHOOD LEUKAEMIA IS OF NO CLINICAL VALUE. / Pui, Ching Hon; Paul Bowman, W.; Abromowitch, Minnie; Dahl, Gary V.; Rao, Bhaskar N.; Ochs, Judith; Rivera, Gaston.

In: The Lancet, Vol. 326, No. 8452, 24.08.1985, p. 410-412.

Research output: Contribution to journalArticle

TY - JOUR

T1 - ELECTIVE TESTICULAR BIOPSY DURING CHEMOTHERAPY FOR CHILDHOOD LEUKAEMIA IS OF NO CLINICAL VALUE

AU - Pui, Ching Hon

AU - Paul Bowman, W.

AU - Abromowitch, Minnie

AU - Dahl, Gary V.

AU - Rao, Bhaskar N.

AU - Ochs, Judith

AU - Rivera, Gaston

PY - 1985/8/24

Y1 - 1985/8/24

N2 - The clinical value of early detection of testicular leukaemia was assessed by elective wedge biopsy during the 12th or 18th month of therapy in children with acute lymphoblastic leukaemia. Biopsy samples were taken in 106 of 238 consecutively treated boys who attained complete remission; only 1 had occult disease. Samples were also taken in 2 boys with testicular leukaemia at diagnosis as soon as they achieved complete remission, and in 14 others at the end of therapy; none showed evidence of leukaemic infiltration. 13 boys, including the 1 with biopsy-confirmed occult disease, had a testicular relapse; 6 of these patients had had negative biopsy findings 12-28 months before relapse. These results indicate that elective testicular biopsy during therapy for childhood leukaemia is of no benefit clinically. They also suggest that routine use of end-of-therapy testicular biopsy should be re-evaluated, since frequency of testicular relapse is low, therapy is effective, and negative biopsy findings do not preclude eventual relapse.

AB - The clinical value of early detection of testicular leukaemia was assessed by elective wedge biopsy during the 12th or 18th month of therapy in children with acute lymphoblastic leukaemia. Biopsy samples were taken in 106 of 238 consecutively treated boys who attained complete remission; only 1 had occult disease. Samples were also taken in 2 boys with testicular leukaemia at diagnosis as soon as they achieved complete remission, and in 14 others at the end of therapy; none showed evidence of leukaemic infiltration. 13 boys, including the 1 with biopsy-confirmed occult disease, had a testicular relapse; 6 of these patients had had negative biopsy findings 12-28 months before relapse. These results indicate that elective testicular biopsy during therapy for childhood leukaemia is of no benefit clinically. They also suggest that routine use of end-of-therapy testicular biopsy should be re-evaluated, since frequency of testicular relapse is low, therapy is effective, and negative biopsy findings do not preclude eventual relapse.

UR - http://www.scopus.com/inward/record.url?scp=0022006205&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(85)92735-7

DO - 10.1016/S0140-6736(85)92735-7

M3 - Article

C2 - 2863443

AN - SCOPUS:0022006205

VL - 326

SP - 410

EP - 412

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8452

ER -